Windtree Therapeutics Reports Topline Results From Phase 2B SEISMiC Extension Study Of Istaroxime In Early Cardiogenic Shock; Istaroxime Significantly Improves Systolic Blood Pressure Over Six Hours And Shows Notable Secondary Endpoint Improvements
Portfolio Pulse from Benzinga Newsdesk
Windtree Therapeutics announced positive topline results from its Phase 2B SEISMiC extension study of Istaroxime in early cardiogenic shock. The study showed significant improvements in systolic blood pressure over six hours and notable secondary endpoint improvements.
September 25, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Windtree Therapeutics' Phase 2B study of Istaroxime in early cardiogenic shock showed significant improvements in systolic blood pressure and secondary endpoints, potentially boosting investor confidence.
The positive results from the Phase 2B study of Istaroxime are likely to boost investor confidence in Windtree Therapeutics, as the drug shows potential in treating early cardiogenic shock. This could lead to increased interest and a positive short-term impact on WINT's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100